Antidepressant Treatment for Late-Life Depression: Considering Risks and Benefits

Eric J. Lenze; Hanadi Ajam Oughli

doi:10.1111/jgs.15964

Antidepressant Treatment for Late-Life Depression: Considering Risks and Benefits

Eric J. Lenze, Hanadi Ajam Oughli

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	1555-1556
Number of pages	2
Journal	Journal of the American Geriatrics Society
Volume	67
Issue number	8
DOIs	https://doi.org/10.1111/jgs.15964
State	Published - 2019

Access to Document

10.1111/jgs.15964

Cite this

@article{61038ecccc1c4b46a917a6c99a7367fe,

title = "Antidepressant Treatment for Late-Life Depression: Considering Risks and Benefits",

author = "Lenze, {Eric J.} and {Ajam Oughli}, Hanadi",

note = "Funding Information: Conflict of Interest: Eric J. Lenze has received research support from the National Institutes of Health, the Food and Drug Administration, McKnight Brain Research Foundation, Taylor Family Institute for Innovative Psychiatric Research, Center for Brain Research in Mood Disorders, Barnes Jewish Foundation, Takeda, Lundbeck, Janssen, and Alkermes. He has been a consultant for Janssen and Jazz Pharmaceuticals. Hanadi Ajam Oughli has no financial disclosures. Funding Information: Sponsor{\textquoteright}s Role: This publication was supported by funding from the National Institutes of Health and the Taylor Family Institute for Innovative Psychiatric Research and Center for Brain Research in Mood Disorders (at Washington University) to Eric J. Lenze. The funding source(s) had no role in the preparation, review, or approval of the manuscript.",

year = "2019",

doi = "10.1111/jgs.15964",

language = "English",

volume = "67",

pages = "1555--1556",

journal = "Journal of the American Geriatrics Society",

issn = "0002-8614",

number = "8",

}

TY - JOUR

T1 - Antidepressant Treatment for Late-Life Depression

T2 - Considering Risks and Benefits

AU - Lenze, Eric J.

AU - Ajam Oughli, Hanadi

N1 - Funding Information: Conflict of Interest: Eric J. Lenze has received research support from the National Institutes of Health, the Food and Drug Administration, McKnight Brain Research Foundation, Taylor Family Institute for Innovative Psychiatric Research, Center for Brain Research in Mood Disorders, Barnes Jewish Foundation, Takeda, Lundbeck, Janssen, and Alkermes. He has been a consultant for Janssen and Jazz Pharmaceuticals. Hanadi Ajam Oughli has no financial disclosures. Funding Information: Sponsor’s Role: This publication was supported by funding from the National Institutes of Health and the Taylor Family Institute for Innovative Psychiatric Research and Center for Brain Research in Mood Disorders (at Washington University) to Eric J. Lenze. The funding source(s) had no role in the preparation, review, or approval of the manuscript.

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85066500476&partnerID=8YFLogxK

U2 - 10.1111/jgs.15964

DO - 10.1111/jgs.15964

M3 - Editorial

C2 - 31140584

AN - SCOPUS:85066500476

SN - 0002-8614

VL - 67

SP - 1555

EP - 1556

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

IS - 8

ER -

Antidepressant Treatment for Late-Life Depression: Considering Risks and Benefits

Access to Document

Other files and links

Cite this